Leading the Way in Life Science Technologies

GEN Exclusives

More »

Mar. 15, Vol. 25, No. 6

    • Point of View

      • Misplaced Attacks on the Pharmaceutical Industry
      • The pharmaceutical industry used to enjoy the luxury of going about its business in relative obscurity. To be sure, the industry faced critical issues, like the level of oversight the FDA should exercise over new drug applications—but these matters ... more »
    • Feature Articles

      • Addressing Stability of Biological Drugs
      • Forced degradation studies involve exposing a drug substance to harsher conditions than the product would be expected to experience and determining at what point and how it degrades. Identifying strategies to minimize the effects of variable temper ... more »
      • Biotech in Wales Quietly Thriving
      • Sophia Fox
      • Ask any scientist in the know to name a few major biotech clusters in Great Britain and the geographical areas most likely to spring to mind include Oxford and Cambridge in England, and Edinburgh in Scotland. Bioscience clusters in Wales have tradit ... more »
      • Lab Automation 101: Effective Integration
      • One of the highlights of "Lab Automation 2005" was the discussion of such topics as planning and executing successful automation projects, the strategies and technical features that make up a successful automated system, up and downstream ... more »
      • Screening Technology Challenges
      • Susan Aldridge, Ph.D.
      • Screening of compounds for drug activity and other properties is an important discipline involving chemistry, biochemistry, and physics. Fast, effective, and informative screening technology can enable companies to fail early and cheap when it comes ... more »
      • Using Nanotechnologies In Biotech and Medicine
      • Of the 2004 global investment of $8.6 billion in nanotechnology, the earliest real payoffs may come from the biotechnology and pharmaceutical industries. Materials that exist in nanospace (generally defined as in the range of 100 nanometers to 0.1 ... more »
    • FDA News and Analysis

      • FDA Final Current Good Tissue Practice Rule
      • May 25 will mark the end of the beginning for FDA regulation of human cells, tissues, and cellular and tissue-based products (HCT/Ps). The last and, in some respects, most important of its panoply of regulations to govern the collection of anteceden ... more »

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »